Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

PA Cohen; A Powell; S Böhm; CB Gilks; CJR Stewart; TM Meniawy; M Bulsara; S Avril; EC Brockbank; T Bosse; GR de Azevedo Focchi; R Ganesan; RM Glasspool; BE Howitt; HS Kim; JY Lee; ND Le; M Lockley; R Manchanda; T Mandalia; WG McCluggage; I McNeish; D Midha; R Srinivasan; YY Tan; R van der Griend; M Yunokawa; GF Zannoni; S Aggarwal; H Bronger; EB Brown; M Buck; SA Bukhari; E Coghlan; N Cope; MS de Almeida; CD De Kroon; A Dean; MJ Devlin; HM Ditzel; E Drecoll; A Fagotti; A Faruqi; L Feeney; K Gupta; I Harley; F Inzani; AR Jeyarajah; MHE Koay; JR Kroep; Y Leung; AR Loft; D MaGee; S McKenna; D Millan; J Millar; R Miller; GR Mohan; S Mughal; SM Nicolau; J Nevin; AS Oakley; M Quigley; B Rai; A Rajwanshi; SG Salfinger; G Scambia; K Scatchard; B Schmalfeldt; B Simcock; P Singh; KC Strickland; V Suri; S Syed; P Sykes; A Tan; J Tan; E Thompson; AV Tinker; G Trevisan; MGBK Uyeda; MM Vaughan; W Weichert; A Williams; S Williams; PC Zorzato; N Singh

Journal article

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

PA Cohen, A Powell, S Böhm, CB Gilks, CJR Stewart, TM Meniawy, M Bulsara, S Avril, EC Brockbank, T Bosse, GR de Azevedo Focchi, R Ganesan, RM Glasspool, BE Howitt, HS Kim, JY Lee, ND Le, M Lockley, R Manchanda, T Mandalia Show all

Gynecologic Oncology | Published : 2019

DOI: 10.1016/j.ygyno.2019.04.679

Abstract

Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow..

View full abstract